Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
VPS35 mutations in Parkinson disease.
Validation of the freezing of gait questionnaire in patients with Parkinson's disease
FOG‐Q was a reliable tool for the assessment of treatment intervention and was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility.
Antioxidant Therapy in Acute Central Nervous System Injury: Current State
Treatment with antioxidants may theoretically act to prevent propagation of tissue damage and improve both the survival and neurological outcome of acute central nervous system (CNS) injury.
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised,…
The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy
Well-designed clinical studies using antioxidant intake, as well as investigations based on larger cohorts studied over a longer periods of time, are needed in order to assess whether antioxidant intake together with other conventional treatments, might be beneficial in treating MS.
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
- C. Olanow, O. Rascol, E. Tolosa
- Medicine, PsychologyThe New England journal of medicine
- 10 December 2009
Early treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with the two doses were associated with different outcomes, the study results must be interpreted with caution.
The natural history of multiple system atrophy: a prospective European cohort study
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and…
Precursor control of neurotransmitter synthesis.
This relationship allows precursor administration to produce selective physiologic effects by enhancing neurotransmitter release from some but not all of the neurons potentially capable of utilizing the precursor for this purpose, and allows the investigator to predict when administering the precursor might be useful for amplifying a physiologic process, or for treating a pathologic state.